Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge represents Apax Partners LLP in connection with the acquisition of stakes in Unilabs
Mandate

Vinge represents Apax Partners LLP in connection with the acquisition of stakes in Unilabs

December 16, 2016 M&A

Vinge, together with Simpson Thacher & Bartlett LLP, represents Apax Partners LLP in connection with the divestment by private equity funds Nordic Capital Fund VI and Apax France VII of their respective stakes in Unilabs to Apax IX, advised by Apax Partners LLP.

Unilabs is with over 5,300 employees and 112 laboratories one of Europe’s leading medical diagnostics businesses. Unilabs generated annual revenues of €673 million in 2015.

The transaction is subject to regulatory approvals and the financial terms of the transaction are not being disclosed.

The Vinge team includes partner Jonas Johansson together with, among others, Alex Miler and Rasmus Perdahl.

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

 Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

 Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025